Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jan 12, 2024 4:26pm
126 Views
Post# 35824386

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 monthsmisleading for sure especially when Matt himself said that he expected to be running 2 phase 3 trials starting in 2023. Now it's anticipation for panc and only guidance for the phase 3. Not making any of this up,just the facts. And quentin is right , they could have started the trial 6 years ago and even stated such in their older pr's if you care to actually take a look.
I'll make you a bet, I bet when the circular for the AGM comes out the Management gives themselves another well deserved raise. Now that's taking care of the shareholders and adding value for sure. The addition on the bod is good but at the same time they should have gotten rid of at least one yes person who has no shares or interest in the company IMO.
As for MM's controlling the price, you don't even need them for the price to go down, there is just no shareholder support as we have no institutions other than a hedge fund to support the price.
Let's see if they actually start the phase 3 this june with a partner.
<< Previous
Bullboard Posts
Next >>